Salix Pharmaceuticals

RELISTOR

Manufacturer:

Salix Pharmaceuticals

Relistor HCPCS:

J2212

HCPCS Code Descriptor:

Injection, methylnaltrexone, 0.1 mg

Category:

J Code

Relistor NDCs:

65649-0551-03, 65649-0552-04, 65649-0551-02, 65649-0551-07

Primary Type:

Gastrointestinal

Generic/Specialty Status:

Single-Source

Package Type:

Not Found

Route of Administration:

Subcutaneous

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

65649-0551-03, 65649-0552-04

About Relistor:

RELISTOR is a Gastrointestinal drug manufactured by Salix Pharmaceuticals and administered via the Subcutaneous route of administration. The J Code: J2212 is aligned to the drug RELISTOR.

Relistor is a type of medication called a gut motility stimulator. It is often prescribed to patients who have constipation caused by opioid medications. Relistor is thought to reduce and treat constipation caused by narcotic medications without reducing the pain-relieving effects. Relistor is approved for patients who take pain relieving medications for chronic, non-cancer related pain.

ACCESS PRICING AND MORE BY REGISTERING

J2212 Added Date:

January 1, 2013

J2212 Effective Date:

January 1, 2013

J2212 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Relistor billing and coding information.
Relistor patient assistance information can be found through Bausch Health’s Patient Assistance Program at the URL: http://www.bauschhealthpap.com
RELISTOR prescribing information can be found at the link below:
Information regarding RELISTOR’s side effects can be found at MedlinePlus